According to the latest report by IMARC Group, titled "RNA Interference Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global RNA interference drug delivery market reached a value of US$ 54.74 Billion in 2021. RNA interference (RNAi) drug delivery refers to a method of drug administration that assists in monitoring mutations or gene expression. It is generally administered via intravenous, intra-dermal and intraperitoneal injections methods. RNAi is a post-transcriptional gene modulation strategy that helps in diagnosing and treating chronic diseases. Additionally, it also assists laboratory professionals in determining gene functions and developing therapeutic solutions. As a result, it aids in suppressing the growth of tumors, limiting viral infections via silencing of viral genes for regulating the cellular defense function and dysregulation of genes for smooth muscle functioning in cardiovascular diseases.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global RNA Interference Drug Delivery Market Trends:
The global market is primarily driven by the rising prevalence of chronic diseases among the masses. Coupled with the increasing occurrences of viral infections and the rapid outbreak of coronavirus disease (COVID-19) across the globe, this has propelled the market growth. Furthermore, various technological advancements and continuous product innovations, such as the introduction of innovative synthetic bio-vectors and delivery carriers, are providing an impetus to the market growth. Moreover, significant growth in biotechnology and the increasing investments in RNAi therapeutic development are creating a positive outlook for the market. In line with this, the rising funding activities by prominent companies for conducting extensive research and development (R&D) activities are providing a boost to the market growth. Other factors, including the increasing number of research laboratories and diagnostic centers across the globe, the rising healthcare expenditure and continuous improvements in the healthcare infrastructure, are further projected to drive the market growth. On account of the aforementioned factors,the market is anticipated to reach a value of US$ 184.98 Billion by 2027, growing at a CAGR of 22.5% during 2022-2027.
- Based on the application, the market has been segmented into infectious disease, cardiology, oncology, neurology, ophthalmology, urology, metabolic disorders and others.
- On the basis of the technology, the market has been segregated into nanoparticle, pulmonary, nucleic acid and aptamer drug deliveries.
- Based on the region, the market has been divided into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800